Pluristem Therapeutics Inc (Pluristem) is a clinical-stage biotechnology company. Pluristem uses placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for a broad spectrum of diseases. Pluristem derives its cell products from human placental cells. Pluristem’s pipeline targets multiple indications involving inflammation and ischemia, including peripheral artery disease, muscle injury, preeclampsia, and graft versus host disease. PLX cells are a cell therapy product defined as mesenchymal-like adherent stromal cells (ASCs) derived from full term human placentas. Pluristem manufactures placenta-based cell products using a 3D bioreactor. Pluristem is pursuing multiple indications including Cardiovascular, Orthopedic, Pulmonary and Hematological diseases as well as preeclampsia. Through Pluristem’s in-house manufacturing facility the Company produces homogeneous, clinical-grade cells.